Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report, Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 70 molecules. Out of which approximately 59 molecules are developed by companies and remaining by the universities/institutes.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The report outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 8, 28 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Lewy Body Dementia, Alzheimer's Disease, Neurodegenerative Diseases, Familial Amyloid Neuropathies, Amyloidosis, Autism, Chronic Traumatic Encephalopathy (CTE), Constipation, Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), Dementia, Dementia Associated With Alzheimer's Disease, Frontotemporal Dementia (FTD), Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Progressive Supranuclear Palsy, Psychosis, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report, Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 70 molecules. Out of which approximately 59 molecules are developed by companies and remaining by the universities/institutes.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
The report outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 8, 28 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Lewy Body Dementia, Alzheimer's Disease, Neurodegenerative Diseases, Familial Amyloid Neuropathies, Amyloidosis, Autism, Chronic Traumatic Encephalopathy (CTE), Constipation, Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), Dementia, Dementia Associated With Alzheimer's Disease, Frontotemporal Dementia (FTD), Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Progressive Supranuclear Palsy, Psychosis, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
ABL Bio Inc
AC Immune SA
Alterity Therapeutics Ltd
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arvinas Inc
AstraZeneca Plc
AUM LifeTech Inc
BioArctic AB
Chimerna Therapeutics Inc
DegenRx BV
Denali Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterin Inc
Fulcrum Therapeutics Inc
Genmab AS
ICB International Inc
Ionis Pharmaceuticals Inc
ND Biosciences SA
Neuramedy Co Ltd
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Nuravax Inc
Prazer Therapeutics
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
ResQ Biotech
Seelos Therapeutics, Inc.
Selonterra Inc
Shape Therapeutics Inc
Synapss Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Treventis Corp
UCB SA
UniQure NV
Vaxxinity Inc
Wren Therapeutics Ltd
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
AAV hmAb 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABBV-0805 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACI-5755 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACI-7104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha Syn Degrader - Drug Profile
Product Description
Mechanism Of Action
Alpha Synuclein - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha-Synuclein - Drug Profile
Product Description
Mechanism Of Action
AMT-210 - Drug Profile
Product Description
Mechanism Of Action
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense RNAi Oligonucleotides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANVS-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Aptamer to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ASOA-19 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATV:aSyn - Drug Profile
Product Description
Mechanism Of Action
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
buntanetap tartrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-terminal Alpha Synuclein - Drug Profile
Product Description
Mechanism Of Action
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ION-464 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Morphomer a-Syn - Drug Profile
Product Description
Mechanism Of Action
ND-001 - Drug Profile
Product Description
Mechanism Of Action
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NM-401 - Drug Profile
Product Description
Mechanism Of Action
NM-402 - Drug Profile
Product Description
Mechanism Of Action
NM-403 - Drug Profile
Product Description
Mechanism Of Action
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Parkinson's Disease (SNCA A53T, LRRK2 G2019S) - Drug Profile
Product Description
Mechanism Of Action
PD-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PD-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PD-1602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PMN-442 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-003 - Drug Profile
Product Description
Mechanism Of Action
PR-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
prasinezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRI-100 - Drug Profile
Product Description
Mechanism Of Action
PRX-303 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Peptides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
SHP-201 - Drug Profile
Product Description
Mechanism Of Action
SLS-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SLS-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Alpha Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
SMQ-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SNP-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56286 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56287 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UB-312 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UCB-0599 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UCB-7853 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Discontinued Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2022: Alterity Therapeutics announces presentation of data from the bioMUSE natural history study at the American Autonomic Society Annual Meeting
Oct 26, 2022: Alterity Therapeutics announces presentation of MRI data from the bioMUSE natural history study at the American Neurological Association Annual Meeting
Oct 14, 2022: Alterity Therapeutics obtains approval in Australia to begin MSA therapy
Oct 11, 2022: Annovis Bio announces publication of phase 2a clinical data in The Journal of Prevention of Alzheimer's Disease
Oct 06, 2022: Annovis Bio announces FDA authorization to proceed with phase 2/3 trial for buntanetap in Alzheimer's Disease
Sep 26, 2022: Alterity Therapeutics announces presentation of wearable sensor data from the bioMUSE natural history study at the International Congress of Parkinson's Disease and Movement Disorders
Sep 20, 2022: Alterity Therapeutics receives U.S. FDA approval for Investigational New Drug application for ATH434 for the treatment of Multiple System Atrophy
Sep 13, 2022: Annovis Bio announces publication of patents covering the treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
Aug 25, 2022: Alterity begins Phase II multiple system atrophy therapy trial in UK
Aug 24, 2022: Annovis Bio doses first subject in Phase III Parkinson’s trial
Aug 24, 2022: Seelos Therapeutics receives a research and development grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
Jul 08, 2022: Annovis Bio receives FDA notice to advance Phase III Parkinson’s trial
Jul 06, 2022: Alterity Therapeutics doses first patient in ATH434 phase 2 clinical trial in multiple system atrophy
Jun 30, 2022: Alterity receives a $4.1 million R&D Tax Incentive Refund
Jun 24, 2022: Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
ABL Bio Inc
AC Immune SA
Alterity Therapeutics Ltd
Annovis Bio Inc
Aprinoia Therapeutics Inc
Arvinas Inc
AstraZeneca Plc
AUM LifeTech Inc
BioArctic AB
Chimerna Therapeutics Inc
DegenRx BV
Denali Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Enterin Inc
Fulcrum Therapeutics Inc
Genmab AS
ICB International Inc
Ionis Pharmaceuticals Inc
ND Biosciences SA
Neuramedy Co Ltd
Neurimmune Holding AG
Neuropore Therapies Inc
nLife Therapeutics SL
Nuravax Inc
Prazer Therapeutics
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
ResQ Biotech
Seelos Therapeutics, Inc.
Selonterra Inc
Shape Therapeutics Inc
Synapss Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Treventis Corp
UCB SA
UniQure NV
Vaxxinity Inc
Wren Therapeutics Ltd
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
AAV hmAb 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABBV-0805 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACI-5755 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACI-7104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AHT-434 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha Syn Degrader - Drug Profile
Product Description
Mechanism Of Action
Alpha Synuclein - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha-Synuclein - Drug Profile
Product Description
Mechanism Of Action
AMT-210 - Drug Profile
Product Description
Mechanism Of Action
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense RNAi Oligonucleotides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANVS-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Aptamer to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ASOA-19 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATV:aSyn - Drug Profile
Product Description
Mechanism Of Action
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
buntanetap tartrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-terminal Alpha Synuclein - Drug Profile
Product Description
Mechanism Of Action
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ION-464 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies to Inhibit Alpha Synuclein for Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Morphomer a-Syn - Drug Profile
Product Description
Mechanism Of Action
ND-001 - Drug Profile
Product Description
Mechanism Of Action
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NM-401 - Drug Profile
Product Description
Mechanism Of Action
NM-402 - Drug Profile
Product Description
Mechanism Of Action
NM-403 - Drug Profile
Product Description
Mechanism Of Action
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Parkinson's Disease (SNCA A53T, LRRK2 G2019S) - Drug Profile
Product Description
Mechanism Of Action
PD-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PD-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PD-1602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PMN-442 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-003 - Drug Profile
Product Description
Mechanism Of Action
PR-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
prasinezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
PRI-100 - Drug Profile
Product Description
Mechanism Of Action
PRX-303 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Peptides to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
SHP-201 - Drug Profile
Product Description
Mechanism Of Action
SLS-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SLS-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Alpha Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
SMQ-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SNP-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56286 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TEV-56287 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UB-312 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UCB-0599 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UCB-7853 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Discontinued Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2022: Alterity Therapeutics announces presentation of data from the bioMUSE natural history study at the American Autonomic Society Annual Meeting
Oct 26, 2022: Alterity Therapeutics announces presentation of MRI data from the bioMUSE natural history study at the American Neurological Association Annual Meeting
Oct 14, 2022: Alterity Therapeutics obtains approval in Australia to begin MSA therapy
Oct 11, 2022: Annovis Bio announces publication of phase 2a clinical data in The Journal of Prevention of Alzheimer's Disease
Oct 06, 2022: Annovis Bio announces FDA authorization to proceed with phase 2/3 trial for buntanetap in Alzheimer's Disease
Sep 26, 2022: Alterity Therapeutics announces presentation of wearable sensor data from the bioMUSE natural history study at the International Congress of Parkinson's Disease and Movement Disorders
Sep 20, 2022: Alterity Therapeutics receives U.S. FDA approval for Investigational New Drug application for ATH434 for the treatment of Multiple System Atrophy
Sep 13, 2022: Annovis Bio announces publication of patents covering the treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
Aug 25, 2022: Alterity begins Phase II multiple system atrophy therapy trial in UK
Aug 24, 2022: Annovis Bio doses first subject in Phase III Parkinson’s trial
Aug 24, 2022: Seelos Therapeutics receives a research and development grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
Jul 08, 2022: Annovis Bio receives FDA notice to advance Phase III Parkinson’s trial
Jul 06, 2022: Alterity Therapeutics doses first patient in ATH434 phase 2 clinical trial in multiple system atrophy
Jun 30, 2022: Alterity receives a $4.1 million R&D Tax Incentive Refund
Jun 24, 2022: Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ABL Bio Inc, 2022
Pipeline by AC Immune SA, 2022
Pipeline by Alterity Therapeutics Ltd, 2022
Pipeline by Annovis Bio Inc, 2022
Pipeline by Aprinoia Therapeutics Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by AUM LifeTech Inc, 2022
Pipeline by BioArctic AB, 2022
Pipeline by Chimerna Therapeutics Inc, 2022
Pipeline by DegenRx BV, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Enterin Inc, 2022
Pipeline by Fulcrum Therapeutics Inc, 2022
Pipeline by Genmab AS, 2022
Pipeline by ICB International Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by ND Biosciences SA, 2022
Pipeline by Neuramedy Co Ltd, 2022
Pipeline by Neurimmune Holding AG, 2022
Pipeline by Neuropore Therapies Inc, 2022
Pipeline by nLife Therapeutics SL, 2022
Pipeline by Nuravax Inc, 2022
Pipeline by Prazer Therapeutics, 2022
Pipeline by Priavoid GmbH, 2022
Pipeline by Primary Peptides Inc, 2022
Pipeline by Proclara Biosciences Inc, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by Prothena Corp Plc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Seelos Therapeutics, Inc., 2022
Pipeline by Selonterra Inc, 2022
Pipeline by Shape Therapeutics Inc, 2022
Pipeline by Synapss Therapeutics Inc, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Treventis Corp, 2022
Pipeline by UCB SA, 2022
Pipeline by UniQure NV, 2022
Pipeline by Vaxxinity Inc, 2022
Pipeline by Wren Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by ABL Bio Inc, 2022
Pipeline by AC Immune SA, 2022
Pipeline by Alterity Therapeutics Ltd, 2022
Pipeline by Annovis Bio Inc, 2022
Pipeline by Aprinoia Therapeutics Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by AUM LifeTech Inc, 2022
Pipeline by BioArctic AB, 2022
Pipeline by Chimerna Therapeutics Inc, 2022
Pipeline by DegenRx BV, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Enterin Inc, 2022
Pipeline by Fulcrum Therapeutics Inc, 2022
Pipeline by Genmab AS, 2022
Pipeline by ICB International Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by ND Biosciences SA, 2022
Pipeline by Neuramedy Co Ltd, 2022
Pipeline by Neurimmune Holding AG, 2022
Pipeline by Neuropore Therapies Inc, 2022
Pipeline by nLife Therapeutics SL, 2022
Pipeline by Nuravax Inc, 2022
Pipeline by Prazer Therapeutics, 2022
Pipeline by Priavoid GmbH, 2022
Pipeline by Primary Peptides Inc, 2022
Pipeline by Proclara Biosciences Inc, 2022
Pipeline by ProMIS Neurosciences Inc, 2022
Pipeline by Prothena Corp Plc, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Seelos Therapeutics, Inc., 2022
Pipeline by Selonterra Inc, 2022
Pipeline by Shape Therapeutics Inc, 2022
Pipeline by Synapss Therapeutics Inc, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Treventis Corp, 2022
Pipeline by UCB SA, 2022
Pipeline by UniQure NV, 2022
Pipeline by Vaxxinity Inc, 2022
Pipeline by Wren Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
